These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29378299)

  • 1. Advances in targeted therapies 2017.
    Breedveld FC; Kalden JR; Smolen JS
    Clin Immunol; 2018 Jan; 186():1-2. PubMed ID: 29378299
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalizing medicine for autoimmune and inflammatory diseases.
    Chan AC; Behrens TW
    Nat Immunol; 2013 Feb; 14(2):106-9. PubMed ID: 23334822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor-1α: a promising therapeutic target for autoimmune diseases.
    Guan SY; Leng RX; Tao JH; Li XP; Ye DQ; Olsen N; Zheng SG; Pan HF
    Expert Opin Ther Targets; 2017 Jul; 21(7):715-723. PubMed ID: 28553732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.
    Ostrov BE
    Immunol Invest; 2015; 44(8):777-802. PubMed ID: 26575464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.
    Kazatchkine MD; Kaveri SV
    N Engl J Med; 2001 Sep; 345(10):747-55. PubMed ID: 11547745
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemokine axis as a therapeutic target to enhance the recruitment of Tregs and treat organ-specific autoimmune and inflammatory diseases.
    Bayry J
    Immunotherapy; 2012 Jan; 4(1):9-12. PubMed ID: 22149994
    [No Abstract]   [Full Text] [Related]  

  • 7. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial overview: Autoimmunity: A new frontier awaits.
    Stetson DB
    Curr Opin Immunol; 2018 Dec; 55():iii-iv. PubMed ID: 30522628
    [No Abstract]   [Full Text] [Related]  

  • 9. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies.
    Maddur MS; Miossec P; Kaveri SV; Bayry J
    Am J Pathol; 2012 Jul; 181(1):8-18. PubMed ID: 22640807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Th17 cells in autoimmune diseases.
    Han L; Yang J; Wang X; Li D; Lv L; Li B
    Front Med; 2015 Mar; 9(1):10-9. PubMed ID: 25652649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADDR Editor's Collection 2017.
    Ghandehari H
    Adv Drug Deliv Rev; 2017 Dec; 122():1. PubMed ID: 29197465
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical considerations for the use of IGIV therapy: introduction.
    Shah S
    Am J Health Syst Pharm; 2005 Aug; 62(16 Suppl 3):S3-4. PubMed ID: 16100385
    [No Abstract]   [Full Text] [Related]  

  • 13. The autoinflammatory side of systemic sclerosis.
    De Santis M; Selmi C
    Isr Med Assoc J; 2015 Jan; 17(1):47-9. PubMed ID: 25739177
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting Treg signaling for the treatment of autoimmune diseases.
    Spence A; Klementowicz JE; Bluestone JA; Tang Q
    Curr Opin Immunol; 2015 Dec; 37():11-20. PubMed ID: 26432763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced killing activity of regulatory T cells ameliorates inflammation and autoimmunity.
    Askenasy N
    Autoimmun Rev; 2013 Aug; 12(10):972-5. PubMed ID: 23684702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
    Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases.
    DelaRosa O; Dalemans W; Lombardo E
    Curr Opin Biotechnol; 2012 Dec; 23(6):978-83. PubMed ID: 22682584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of autoimmune diseases: pathophysiologic insights from genetics and implications for new therapies.
    Cho JH; Feldman M
    Nat Med; 2015 Jul; 21(7):730-8. PubMed ID: 26121193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineutrophil cytoplasmic antibody-associated vasculitis: autoinflammation, autodestruction and autoimmunity--key to new therapies.
    Lamprecht P; Gross WL
    Trends Immunol; 2008 Dec; 29(12):587-8. PubMed ID: 18951843
    [No Abstract]   [Full Text] [Related]  

  • 20. [112th Scientific Meeting of the Japanese Society of Internal Medicine: Educational Lecture: Diagnosis and Therapy for Autoinflammatory Syndrome].
    Ida H
    Nihon Naika Gakkai Zasshi; 2015 Sep; 104(9):1964-73. PubMed ID: 30160907
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.